NSG 533 Exam 3 2026/2027 – 130+ Questions & Verified Answers | Heart Failure, CAD, Hypertension, Dementia, Pediatrics & Obesity | Wilkes University

The NSG 533 Exam 3 2026/2027 Advanced Pharmacology Guide is a comprehensive 31-page study resource with 130+ questions and verified answers designed around major cardiovascular, neurologic, pediatric, and metabolic concepts covered in NSG 533 at Wilkes University. The material emphasizes clinically relevant pathophysiology and pharmacology, including heart failure, coronary artery disease (CAD), atherosclerosis, acute coronary syndromes, hypertension, dementia, delirium, pediatric gastrointestinal and genitourinary disorders, lead toxicity, obesity, adipose physiology, and cardiovascular hemodynamics. The uploaded document identifies itself as a Grade A, 100% correct guide with verified solutions for the 2026/2027 course update. A major section concentrates on heart failure pathophysiology and pharmacologic targets. It reviews the universal stages of heart failure, HFrEF versus HFpEF, systolic and diastolic dysfunction, ejection fraction, inotropy and lusitropy, right- versus left-sided heart failure manifestations, ventricular remodeling, and compensatory mechanisms involving the Frank-Starling response, sympathetic nervous system, and renin-angiotensin-aldosterone system. Medication-related concepts include beta blockers, ACE inhibitors, inotropes, RAAS inhibition, neprilysin and ARNI therapy, alongside the roles of angiotensin II, aldosterone, catecholamines, natriuretic peptides, bradykinin, nitric oxide, and endothelin. The cardiovascular content extends into coronary artery disease and atherosclerosis, covering dyslipidemia, LDL and HDL function, familial hypercholesterolemia, modifiable and nonmodifiable CAD risk factors, novel cardiovascular risk markers, endothelial dysfunction, foam-cell and fatty-streak formation, fibrous and occlusive plaque development, unstable plaques, thrombosis, and plaque rupture. Students also review stable and unstable angina, NSTEMI, STEMI, myocardial infarction biomarkers, ECG changes, and complications of myocardial infarction, providing an integrated review of cardiovascular disease progression from endothelial injury through acute coronary syndromes. The hypertension section addresses primary, secondary, and isolated systolic hypertension, medications that may contribute to elevated vascular resistance or cardiac output, major risk factors, blood-pressure categories, and mechanisms involving neurohumoral dysfunction, inflammation, insulin resistance, sodium handling, RAAS activity, sympathetic nervous system activity, and peripheral vascular resistance. The material also reviews proper blood-pressure assessment and target-organ consequences involving the heart, brain, kidneys, and eyes. Neurologic material differentiates dementia and delirium, including irreversible dementia categories, Alzheimer’s disease, Lewy body dementia, frontotemporal dementia, progressive cognitive decline, acute changes in attention and awareness, DSM-V delirium criteria, neurotransmitter-altering medications, and the roles of microglia, astrocytes, and oligodendrocytes. This makes the guide particularly useful for distinguishing gradual neurocognitive decline from acute fluctuating cognitive disturbances. The pediatric section covers intussusception, infantile hypertrophic pyloric stenosis, vesicoureteral reflux, and lead poisoning. Questions review age groups, risk factors, characteristic clinical presentations, diagnostic imaging, complications, blood lead levels, and organ systems affected by lead exposure. For example, the material associates intussusception with severe abdominal pain and currant-jelly stool, while pyloric stenosis is reviewed through non-bilious postprandial vomiting, an olive-sized abdominal mass, dehydration, and metabolic alkalosis. The final portion provides a detailed review of obesity and metabolic physiology, including white, brown, beige, and bone-marrow adipose tissue; leptin and adiponectin; adipokines; positive energy balance; obesogens; leptin resistance; orexigenic and anorexigenic mechanisms; and age-associated anorexia. Cardiovascular fundamentals are reinforced through calculations and concepts involving cardiac output, preload, afterload, myocardial contractility, inotropes, vascular compliance, peripheral resistance, and systolic and diastolic blood pressure. Relevant students: Wilkes University NSG 533 students, Advanced Pharmacology students, Family Nurse Practitioner students, Adult-Gerontology Nurse Practitioner students, Psychiatric Mental Health Nurse Practitioner students where applicable, MSN and graduate nursing students, APRN students, and nursing students reviewing cardiovascular pharmacology, pathophysiology, pediatric disorders, neurologic disorders, and metabolic disease for Exam 3. Keywords NSG 533 Exam 3, NSG 533 exam questions, NSG 533 Exam 3 2026, NSG 533 Exam 3 2027, NSG 533 questions and answers, NSG 533 verified answers, Wilkes University NSG 533, advanced pharmacology exam, advanced pharmacology study guide, pharmacology questions and answers, heart failure pharmacology, HFrEF, HFpEF, heart failure pathophysiology, RAAS, beta blockers, ACE inhibitors, neprilysin inhibitors, natriuretic peptides, coronary artery disease, CAD risk factors, atherosclerosis, dyslipidemia, LDL cholesterol, HDL cholesterol, acute coronary syndrome, stable angina, unstable angina, STEMI, NSTEMI, myocardial infarction, hypertension pathophysiology, hypertension pharmacology, blood pressure categories, dementia, delirium, Alzheimer disease, Lewy body dementia, intussusception, pyloric stenosis, vesicoureteral reflux, lead poisoning, obesity pathophysiology, adipose tissue, leptin resistance, adiponectin, cardiac output, preload, afterload, myocardial contractility, vascular compliance, FNP pharmacology, nurse practitioner pharmacology, graduate nursing exam, Exam 3 study guide